Evidence map›Paper›PMID 25890222›Full record

ReviewCancer letters2015

Genomic profiling guides the choice of molecular targeted therapy of pancreatic cancer.

Thomas S Frank, Xiaotian Sun, Yuqing Zhang, Jingxuan Yang, William E Fisher, Marie-Claude Gingras, Min Li

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Cancer letters, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
1.7field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 28 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Article
  6. Enhancing effect ofJournal of ginseng research · 2022
    Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 2 countries.

Thomas S FrankThe Vivian L. Smith Department of Neurosurgery, The University of Texas Medical School at Houston, Houston, TX 77030, USA.
Xiaotian SunThe Vivian L. Smith Department of Neurosurgery, The University of Texas Medical School at Houston, Houston, TX 77030, USA; Department of Medicine, Department of Surgery, The University of Oklahoma Health Sciences Center, 975 NE 10th Street, BRC 1262A, Oklahoma City, OK 73104, USA; Department of Gastroenterology, Changhai Hospital, Second Military Medical University, Shanghai 200433, China.
Yuqing ZhangDepartment of Cancer Biology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Jingxuan YangThe Vivian L. Smith Department of Neurosurgery, The University of Texas Medical School at Houston, Houston, TX 77030, USA; Department of Medicine, Department of Surgery, The University of Oklahoma Health Sciences Center, 975 NE 10th Street, BRC 1262A, Oklahoma City, OK 73104, USA.
William E FisherMichael E. DeBakey Department of Surgery, Baylor College of Medicine, One Baylor Plaza, Houston, TX 77030, USA.
Marie-Claude GingrasMichael E. DeBakey Department of Surgery, Baylor College of Medicine, One Baylor Plaza, Houston, TX 77030, USA; Human Genome Sequencing Center, Baylor College of Medicine, One Baylor Plaza, N1519, Houston, TX 77030, USA. Electronic address: mgingras@bcm.edu.
Min LiThe Vivian L. Smith Department of Neurosurgery, The University of Texas Medical School at Houston, Houston, TX 77030, USA; Department of Medicine, Department of Surgery, The University of Oklahoma Health Sciences Center, 975 NE 10th Street, BRC 1262A, Oklahoma City, OK 73104, USA. Electronic address: min-li@ouhsc.edu.
Baylor College of Medicine · USUniversity of Oklahoma Health Sciences Center · USChanghai Hospital · CNThe University of Texas MD Anderson Cancer Center · US

Funding

The Human Genome Sequencing CenterU54HG003273 · NHGRI · BAYLOR COLLEGE OF MEDICINE · PI GIBBS, RICHARD A · 2004 to 2015
$341.3M
Role of Dietary Zinc Transporter ZIP4 in Pancreatic CancerR01CA138701 · NCI · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI LI, MIN · 2010 to 2015
$1.5M
NCI NIH HHS R01 CA138701NCI NIH HHS R01CA138701NHGRI NIH HHS U54 HG003273
6 · The paper itself

Abstract

Pancreatic cancer has the worst five-year survival rate of all malignancies due to its aggressive progression and resistance to therapy. Current therapies are limited to gemcitabine-based chemotherapeutics, surgery, and radiation. The current trend toward "personalized genomic medicine" has the potential to improve the treatment options for pancreatic cancer. Gene identification and genetic alterations like single nucleotide polymorphisms and mutations will allow physicians to predict the efficacy and toxicity of drugs, which could help diagnose pancreatic cancer, guide neoadjuvant or adjuvant treatment, and evaluate patients' prognosis. This article reviews the multifaceted roles of genomics and pharmacogenomics in pancreatic cancer.

Indexed as

Gene Expression ProfilingMolecular Targeted TherapyPrecision MedicineAnimalsAntineoplastic AgentsBiomarkers, TumorDrug Resistance, NeoplasmGenetic Predisposition to DiseaseGenomicsHumansPancreatic NeoplasmsPatient SelectionPharmacogeneticsPhenotypePredictive Value of TestsSignal TransductionAntineoplastic AgentsBiomarkers, TumorGene therapyGenomic profilingMutationsPancreatic cancerPharmacogenomicsSLC39A4 (ZIP4)

Identifiers

PMID25890222
PMCPMC4451193
OpenAlexW1964400455

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.